Clinical Trials reports offer expert reviews of the trends and
scientific developments that shape the clinical trial landscape. These
insightful reviews are based on the strategic and scientific clinical
data from Thomson Reuters Cortellis™ Clinical Trials Intelligence.
second edition will focus on the increasing benefits of utilizing
various adaptive trial designs, regulating clinical trial transparency
as well as therapeutic alternatives that are becoming available for
are innovating clinical trial design to be adaptive. The impetus behind
using adaptive design lies in the function: researchers can tell early
on whether a treatment is effective and modify the trial at certain
stages to apply accumulated knowledge, thus making clinical trials more
efficient. Not all trials are conducive to adaptive design so scientists
must take into consideration feasibility, validity, integrity,
efficiency and flexibility.
the same time, there’s a call for more transparency in clinical trials.
Due to increased public distrust, agencies worldwide are developing
ways to enhance transparency. Our report shows that industry and
regulatory agencies must come together to fine-tune the process so that
it benefits all while protecting patients, investors and public health.
This report also reflects on data collected from clinical trial conferences;
American Urological Association and International Urogynecological Association meetings; overactive bladder treatments
Clinical Trial data support the use of a first medical therapy for Peyronie's disease
Missed the last issue? Click here to view the complete set of back issues for the Pharma Matters reports.
You may also be interested in....
The Ones to Watch Quarterly review of the most promising drugs reaching the market and moving between clinical trials. Click here
Spotlight On... Expert
therapy area review of the key market players and deals highlights for
leading areas of industry investment and development. Click here